Publications by authors named "Haruko Daga"

Claim this Profile
[
[Challenges and Prospects for Medical Oncology under the Emerging Infectious Disease Disaster].
Sachi Morita, Noritoshi Kobayashi, Junji Tsurutani, Haruko Daga, Emiko Ohki

Gan To Kagaku Ryoho· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
Zofia Piotrowska, Antonio Passaro, Danny Nguyen, Gerrina Ruiter, Ross A Soo, Haruko Daga

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
J-REGISTER: real-world study of Japanese patients with mutation-positive NSCLC treated with first-line afatinib.
Teppei Yamaguchi, Haruko Daga, Hisashi Tanaka, Takashi Kijima, Masaya Mizushima

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).
Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, Hiroshige Yoshioka, Takehiro Uemura, Haruko Daga

J Thorac Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.
Hiroaki Akamatsu, Tomomi Nishikawa, Yuriko Takeda, Toshihiro Misumi, Tadashi Aoki, Haruko Daga

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50.
Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, Yasushi Fukuda, Akihiro Bessho

JTO Clin Res Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
Kentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi, Yasutaka Watanabe, Haruko Daga

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib.
Shigeki Umemura, Hibiki Udagawa, Takaya Ikeda, Haruyasu Murakami, Haruko Daga

J Thorac Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.
Hiroyasu Kaneda, Haruko Daga, Asuka Okada, Yuki Nakatani, Yoko Tani

Invest New Drugs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, Akito Hata, Hirotaka Matsumoto, Haruko Daga

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Five Cases of Pseudocirrhosis during Eribulin Treatment for Breast Cancer].
Yuko Akaishi, Shinya Tokunaga, Reo Omori, Yuki Nakatani, Ayako Tanaka, Haruko Daga

Gan To Kagaku Ryoho· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga

JAMA Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Haruko Daga

JAMA Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Haruko Daga

Int J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, Toshihide Yokoyama, Hidetoshi Hayashi, Haruko Daga

Int J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Kimio Yonesaka, Hidetoshi Hayashi, Atsushi Nakamura, Yuki Sato, Koichi Azuma, Haruko Daga

Clin Lung Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Masakazu Abe, Takuhiro Yamaguchi, Yukiyoshi Fujita, Tomoyasu Nishimura, Koichi Kitagawa, Haruko Daga

JAMA Netw Open· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Akira Sugimoto, Shingo Matsumoto, Hibiki Udagawa, Ryo Itotani, Yuko Usui, Haruko Daga

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Nobuyuki Katakami, Toshihide Yokoyama, Satoshi Morita, Tatsuro Okamoto, Yoshiko Urata, Haruko Daga

Int J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.
Yoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, Hidenobu Ishii, Haruko Daga

Cancer Manag Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, Daichi Fujimoto, Koichi Azuma, Haruko Daga

Lung Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
Eiji Iwama, Yoshitaka Zenke, Shunichi Sugawara, Haruko Daga, Masahiro Morise

Eur J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Haruko Daga

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Haruko Daga, Hibiki Udagawa

Nature· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L).
Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, Hidetoshi Hayashi, Yuki Sato, Haruko Daga

Cancer Manag Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis